An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment.

Trial Profile

An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 20 Apr 2012 Results will be presented at the 64th Annual Meeting of the American Academy of Neurology (AAN-2012) according to a Biogen Idec media release.
    • 25 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Planned End Date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top